.Attributes Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as total survival, bring about FDA approval and a brand new treatment choice for clients.